Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer
Patients with TNBC, an aggressive subtype of breast cancer, have limited treatment options beyond standard chemotherapy. High TROP2 expression has been reported in up to 80 percent of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.